Brain ischemia is a condition that occurs when there is not enough blood flow to the brain. This condition leads to limited oxygen supply (cerebral hypoxia) and causes the death of brain tissue. Alpha mangostin (MGS) is a xanthone compound that was found to have neuroprotective activity <i>in vitro</i>, but there are still limitations existing <i>in vivo</i> tests. Recently, we prepared cyclodextrin-based nanoparticles (CDNPs) to solubilize and deliver hydrophobic compounds such as MGS. CDNPs were composed of β type-cyclodextrin (βCD) which is a macrocyclic oligosaccharide with 7 glucose units creating a hydrophilic outer and a hydrophobic cavity. This structure of βCD encapsulates hydrophobic compounds to form a complex in an aqueous solution. Our previous studies showed CDNPs were biocompatible, and its complex with MGS was effective in cancer treatment. Recently, we found that CDNP/MGS decreased infarct volume of brain tissue and deterioration of neurological symptoms in transient middle cerebral artery occlusion model (tMCAO model). In this study, the evidence of presence of MGS in brain tissue, and discuss a mechanism reaching the brain area of CDNP/MGS complex will be discussed.

Novel cyclodextrin-based nanoparticle delivering alpha mangostin to treat brain ischemia

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.